LY517717

Following the clinical approval of novel oral anticoagulants as alternatives to the vitamin K antagonists, many additional novel… (More)

Drug discovery and development is an interdisciplinary, expensive and time-consuming process. Scientific advancements during the… (More)

Anticoagulation is recommended for prophylaxis and treatment of venous thromboembolism (VTE) (deep vein thrombosis and pulmonary… (More)

For the past five decades, there has been little progress in the development of oral anticoagulants, with the choices being… (More)

Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a major cause of morbidity and… (More)

(VTE) and in some countries for the treatment of acute coronary syndromes. Idraparinux, a subcutaneous, longacting, indirect… (More)

BACKGROUND LY517717 is an oral direct inhibitor of activated factor X that is currently under clinical development. OBJECTIVES… (More)

Current anticoagulant provision is dominated by parenteral heparin and oral warfarin, which act by inhibiting several steps of… (More)

Novel anticoagulants to replace unfractionated heparins, low molecular weight heparins and vitamin K antagonists, are needed… (More)

Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism, is a cause of significant mortality and… (More)